Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J L Molitor

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Bulletin Du Cancer|February 1, 1997
[Angiosarcoma of the breast. Apropos of 8 cases and review of the literature]J L Molitor, A Llombart, J M Guinebretière, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCORF Maindrault-Goebel, C Louvet, T André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)F Maindrault-Goebel, A de Gramont, C Louvet, et al.
Infectious Diseases Now|February 16, 2022
Factors associated with hospital admission and adverse outcome for COVID-19: Role of social factors and medical careA-L Beaumont, D Vignes, R Sterpu, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Bulletin Du Cancer|February 1, 1997
[Angiosarcoma of the breast. Apropos of 8 cases and review of the literature]J L Molitor, A Llombart, J M Guinebretière, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2000
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCORF Maindrault-Goebel, C Louvet, T André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR)F Maindrault-Goebel, A de Gramont, C Louvet, et al.
Infectious Diseases Now|February 16, 2022
Factors associated with hospital admission and adverse outcome for COVID-19: Role of social factors and medical careA-L Beaumont, D Vignes, R Sterpu, et al.
Pageof 2